High HSF1 nuclear levels (estimated by immunohistochemistry in patients with invasive breast cancer at diagnosis; in situ carcinomas and stage IV cancers were excluded from the outcome analysis) were previously associated with decreased survival specifically in ER-positive breast cancer patients (Santagata et al., 2011). Here, HSF1 is linked to cancer.